NASDAQ
18.09.26 | 22:00
6,010 US-Dollar
+2,74 % +0,160
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.09. | Shattuck Labs auf Wells Fargo Konferenz: Strategie fokussiert sich auf DR3-Blockade | 2 | Investing.com Deutsch | ||
| 25.08. | What Shattuck Labs Stock Topped the Market on Monday | 3 | The Motley Fool | ||
| 12.08. | H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion | 1 | Investing.com | ||
| 12.08. | H.C. Wainwright senkt Kursziel für Shattuck Labs wegen Studienerweiterung | 3 | Investing.com Deutsch | ||
| 11.08. | Shattuck Labs, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | Shattuck Labs Aktie gibt nach Quartalsbericht nach | 6 | Investing.com Deutsch | ||
| 11.08. | Shattuck Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 11.08. | Shattuck Labs GAAP EPS of -$0.12 in-line | 3 | Seeking Alpha | ||
| 11.08. | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | 510 | GlobeNewswire (Europe) | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| 25.07. | Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday | 1 | The Motley Fool | ||
| 24.07. | This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday | 1 | Benzinga.com | ||
| 24.07. | JPMorgan reiterates Shattuck Labs stock rating on DR3 program | 4 | Investing.com | ||
| 11.06. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Shattuck Labs drops 6%, prices $75M share raise at $4 per share | 1 | Seeking Alpha | ||
| 10.06. | Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr | 318 | AFX News | WASHINGTON (dpa-AFX) - Shattuck Labs, Inc. (STTK), a clinical-stage biotechnology company, on Wednesday revealed the pricing of its earlier announced public offering of 10.88 million shares... ► Artikel lesen | |
| 10.06. | Shattuck Labs prices $75M public offering at $4 per share | 1 | Investing.com | ||
| 10.06. | Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 09.06. | Shattuck Labs commences public offering of common stock | 2 | Investing.com | ||
| 09.06. | Shattuck Labs launches proposed public offering of common stock | 1 | Seeking Alpha |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,863 | +0,63 % | Valneva-Aktie im Check am 18.09. (08:01 Uhr): Meine aktuelle Lageeinschätzung | ||
| PALATIN TECHNOLOGIES | 10,900 | +4,51 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,927 | +3,81 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,095 | -2,23 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,385 | -7,45 % | Mehr als 98% bleiben draußen: Warum Roche, Denali und NurExone neue Wege ins Nervensystem suchen | ||
| SAREPTA THERAPEUTICS | 17,280 | -4,00 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +0,21 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,568 | -4,12 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,272 | +2,64 % | Onco-Innovations Ltd: Onco-Innovations issues 860,168 shares for debt | ||
| OCULAR THERAPEUTIX | 8,750 | -1,13 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERASTEM | 6,510 | -0,97 % | Verastem Oncology stellt auf Konferenz zweigleisige RAS-Strategie vor | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,038 | +1,95 % | Oxford Nanopore Wins Preliminary Injunction Against MGI Tech Over Cyclone Sequencing Systems | ||
| ROCKET PHARMACEUTICALS | 2,940 | -3,61 % | Rocket Pharma upgraded at Needham as FDA OKs pivotal trial design | ||
| VOYAGER THERAPEUTICS | 2,664 | +0,91 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| PALISADE BIO | 1,595 | -6,18 % | Palisade Bio stellt Pläne für CED-Medikament auf Investorenkonferenz vor |
SHATTUCK LABS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,74 % bei einem Aktienkurs von 6,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.